Table 1. Baseline demographic and clinical features .
|
Number of patients/eyes, N/n |
146/289 |
|
Age, mean ± SD (range), years <18 years, N (%) >60 years, N (%) |
37.6 ± 14.4 (4-73) 8 (5.5)* 6 (4.1)** |
|
Sex, N (%) Female Male |
- 60 (41.1) 86 (58.9) |
|
Localization of uveitis, N (%) Anterior uveitis Intermediate uveitis Posterior uveitis Panuveitis |
- 17 (11.6) 8 (5.5) 26 (17.8) 95 (65.1) |
|
Uveitis etiology, N (%) Behçet’s uveitis Sarcoidosis Vogt-Koyanagi-Harada disease Spondyloarthropathy-associated uveitis Serpiginous choroiditis Pars planitis Juvenile idiopathic arthritis-associated uveitis Ampiginous choroiditis Idiopathic uveitis Tubulointerstitial nephritis and uveitis syndrome Sympathetic ophthalmia Tuberculosis-related uveitis Posterior scleritis*** |
- 53 (36.3) 28 (19.2) 18 (12.3) 12 (8.2) 7 (4.8) 6 (4.1) 5 (3.4) 4 (2.7) 4 (2.7) 3 (2.1) 3 (2.1) 2 (1.4) 1 (0.7) |
|
Previous systemic steroid, N (%) None <10 mg/day 16 mg/day 32 mg/day 48 mg/day 64 mg/day |
- 109 (74.7) 12 (8.3) 5 (3.4) 9 (6.2) 2 (1.4) 9 (6.2) |
|
Previous IST/immunomodulatory/biologics****, N (%) None Azathioprine Methotrexate Mycophenolate mofetil Cyclosporine Etanercept Certolizumab Interferon-α |
- 12 (8.2) 57 (39.1) 37 (25.3) 1 (0.7) 51 (34.9) 6 (4.1) 1 (0.7) 18 (12.3) |
|
Line of ADA, N (%) First-line therapy Second-line therapy |
- 12 (8.2) 134 (91.8) |
|
Interval between diagnosis and initiation of ADA treatment, median (IQR), months |
13.5 (7-36) |
|
Duration of ADA treatment; median (IQR), months |
12 (9-24) |
N, Number of patients, n: Number of eyes, SD: Standard deviation, IST: Immunosuppressive treatment, ADA: Adalimumab, IQR: Interquartile range
*Patients started on ADA before the age of 18 years were diagnosed with juvenile idiopathic arthritis-associated uveitis (4 patients), tubulointerstitial nephritis and uveitis syndrome (2 patients), pars planitis (1 patient), and sympathetic ophthalmia (1 patient)
**Among patients over 60 years of age, ADA was initiated in one patient due to Vogt-Koyanagi-Harada and in the remaining five patients due to ocular sarcoidosis
***Posterior scleritis is included under posterior uveitis in the uveitis localization section.
****Some patients received combined ISTs